Leadership team

Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology therapeutics, Jerry has held scientific, pharmaceutical and venture capital positions and has been the CEO or President of multiple biotechnology companies leading novel therapeutic programs from discovery, development to drug approvals for internal and in-licensed products.

From 2016 to late 2021 Jerry was President and CEO of NASDAQ listed Harpoon Therapeutics building the Company from early stage through to IPO, follow-on financings, and development collaborations. Prior to that he held multiple positions, including President and CEO of Kolltan Pharmaceuticals which was acquired by Celldex, Innovative Medicine Head of Oncology and SVP at AstraZeneca-Medimmune, managing a more than $1 billion global R&D budget and President at SUGEN/Pfizer where he was instrumental in invention and full development of several ground-breaking protein kinase inhibitors including sunitinib (Sutent^®).

Jerry has also held academic appointments at the Yale Comprehensive Cancer Center at Yale University, Tufts University School of Medicine, and the Massachusetts Institute of Technology. He received his BS in biology and PhD in the field of biochemistry and genetics from Rensselaer Polytechnic Institute, has authored over 100 scientific and medical publications and is an inventor on over 60 US patents.

Marguerite has over ten years’ extensive experience in leading licensing agreements and collaborations with large, high profile healthcare companies as well as experience in legal and strategic operations. She was previously the Chief Operating Officer and General Counsel of Plexxikon Inc., a member of the Daiichi Sankyo Group, establishing and managing collaborations with Roche, Merck, AstraZeneca, Array and Cancer Research UK. She played a pivotal role in the out-licensing of bezuclastinib to Cogent Biosciences and plixorafenib to Fore Biotherapeutics, securing upfront payments and additional developmental milestones, and royalty payments. She was instrumental in the Phase 3 development and approval of TURALIO^® (pexidartinib), a prescription medicine which is the first and only oral therapy for tenosynovial giant cell tumor. In addition, Marguerite successfully pursued the patent infringement case Plexxikon v. Novartis, resulting in a significant jury verdict award and ongoing royalties from dabrafenib sales.

Marguerite joined STORM from Tatara Therapeutics, where she was Chief Executive Officer, a UCSF spin-out which she set up and raised seed financing. Prior to this, Marguerite was Chief Business Officer at Frontier Medicines Corporation where she oversaw and led all business development activities including a collaboration with AbbVie.

Marguerite received a B.A. from Harvard University and a J.D. from the University of San Diego School of Law and is based in US.

Eric is an accomplished cancer geneticist with over 20 years of experience in oncology research and drug development spanning both academia and industry. He specializes in identifying and implementing biomarker-enabled pre-clinical discovery and clinical development strategies for targeted and immunomodulatory cancer therapies. Dr. Martin has held senior leadership roles at prominent biotechnology companies, including Kinnate Biopharma, Plexxikon, Ignyta, Pfizer Oncology, and Arpeggio Biosciences, where he successfully led multidisciplinary teams through drug discovery, translational research, and early clinical development.

Dr. Martin’s expertise encompasses cancer genetics and clinical genomics, biomarker development, and the use of genetically engineered model systems to understand mechanisms of drug action, resistance, and sensitivity. His contributions have been pivotal in advancing several innovative oncology therapeutics into clinical trials, including, but not limited to, Plixorafenib (PLX-8394), Exarafenib (KIN-2787), Bezuclastinib (PLX-9486) and the FGFR inhibitor KIN-3248.

Dr. Martin received his B.A. in chemistry from the College of the college of the Holy Cross, completed his Ph.D. in Genetics at Thomas Jefferson University’s Kimmel Cancer Institute and pursued postdoctoral training at Harvard Medical School's Dana-Farber Cancer Institute. He has authored numerous peer-reviewed publications, abstracts, and presentations, reflecting his significant contributions to oncology research and drug development.

Sandra Tong is a clinical development innovator with over 25 years of pharma experience across all phases of drug development and multiple therapeutic areas. She has served as Chief Medical Officer in numerous biotech start-ups with deep experience with first-in-class products. She led the clinical development program for a first in human gene therapy treatment in an ultra-rare, monogenic pediatric disease, N-glycanase 1 Deficiency. Previous experience included Vice President of Clinical Sciences and Drug Safety at Rigel Pharmaceuticals, where she was integral in worldwide approvals of Tavalisseä for a rare autoimmune disease. She was Vice President of Clinical Development at Plexxikon Inc. and led multiple early phase oncology trials for innovative targeted, oral small molecules, one leading to approval of Turalioä for a rare soft tissue tumor. Dr. Tong has led clinical programs at Affymax (Omontysä), Johnson and Johnson, Scios Inc., and Roche, with a focus on aligning the science between potential treatments and unmet medical needs.

Sandra received her Bachelor of Science degree at MIT and Doctor of Medicine degree at Johns Hopkins School of Medicine. She was on the faculty at UC-San Francisco as a physician-scientist rheumatologist before entering the pharmaceutical industry.

Leadership team

Jerry McMahon, PhD

Marguerite Hutchinson, J.D.

Eric Martin, PhD

Sandra Tong, MD